
Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

EU COVID-19 antibody ready for clinical trials
CORAT Therapeutics reports the start of production of the first batch of the therapeutic human COVID-19 antibody COR-101 for Phase I testing....

Rentschler Biopharma launches gene therapy subsidiary
Monoclonal antibody specialist Rentschler Biopharma SE is moving forward with the expansion of its geographic footprint and technological porttfolio....

Novel strategy targets chronic liver diseases
The approach published in Nature Cancer leads to a cell-toxic accumulation of saturated fatty acids that drives tumour cells into apoptosis. HCC...

Drug set to rescue COVID-19 patients at ICUs
Initial data from an US expanded access (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...

COVID-19: Moderna reports promising interim results
On Monday, Moderna Inc. announced that two 100µg shots of its mRNA COVID-19 vaccine candidate mRNA-1273 showed an efficacy of 94,5%, according to an...

Centogene and Anylam launch clinical programme
ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....